UCSF Navigation Bar

UCSF Departments of Pathology & Laboratory Medicine Home Page

Lab Manual for UCSF Clinical Laboratories

Lab Manual for SFGH

Internal Resources

Gerard I. Evan, PhD, FRS, FMedSci

Research and Clinical Interests

Our laboratory is interested in the molecular processes that underlie tumorigenesis, tumor progression and tumor maintenance. Cancers appear very different from the normal tissues from which they are presumably derived, and this has engendered the widely held contemporary view that cancers are the protracted end result of a bewildering complexity of molecular lesions that between them drive the formation of the equally complex neoplastic phenotype. However, appearances can be deceiving. We know that many oncogenes are highly pleiotropic "master" switches that modulate a wide variety of mechanistically diverse processes. Consequently, the apparent complexity of cancers may be instructed by a relatively simple, and hence therapeutically tractable, set of molecular lesions. Our overarching aim is to establish what such molecular lesions might be, what effects they have on specific cell types, alone and in combination, and how critical such lesions are not only to drive tumor formation but also to maintain an established tumor.

Selected Publications

  • Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., and Evan, G. I. (2006). The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217.
  • Martins, C. P., Brown-Swigart, L., and Evan, G. I. (2006). Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334.
  • Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., and Evan, G. I. (2006). Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501-514.
  • Soucek, L., Lawlor, E. R., Soto, D., Shchors, K., Swigart, L. B., and Evan, G. I. (2007). Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13, 1211-1218.
  • Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., and Evan, G. I. (2008). Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683.
  • Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A. N., Shchors, K., Bui, D. A., Brown Swigart, L., Johnson, L., and Evan, G. I. (2008). Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell In press.

Selected Awards

  • 1997: Joseph Steiner Prize of the Swiss Oncological Society
  • 1999: Fellow, Academy of Medical Sciences UK
  • 2004: Fellow, The Royal Society of London
  • 2005: Fellow, European Academy of Sciences
  • 2006: Ellison Medical Foundation Senior Scholar
Gerard Evan, PhD, FRS, FMedSci
  • Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology
  • Pathology

Specialty Area

Cancer

Contact Information

  • 513 Parnassus Avenue
  • Room HSW-450A, Box 0502
  • San Francisco, CA 94143-0502

Web Site

Other UCSF Organizational Association(s)

  • Helen Diller Family Comprehensive Cancer Center
  • Department of Cellular & Molecular Pharmacology
UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center